Scarica l'app Stockscreener
9.235
5.74%
-0.515
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$9.75
Aprire:
$9.695
Volume 24 ore:
6.44M
Relative Volume:
1.49
Capitalizzazione di mercato:
$1.50B
Reddito:
$1.08B
Utile/perdita netta:
$422.82M
Rapporto P/E:
4.0504
EPS:
2.28
Flusso di cassa netto:
$-637.33M
1 W Prestazione:
+14.74%
1M Prestazione:
+35.15%
6M Prestazione:
+17.22%
1 anno Prestazione:
-3.77%
Intervallo 1D:
$9.15
$9.70
Intervallo di 1 settimana:
$7.98
$10.13
Portata 52W:
$5.01
$10.64
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Confronta NVAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.235 | 1.58B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.28 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.47 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
818.35 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.26 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Iniziato | Citigroup | Sell |
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Key facts: Novavax signs $30M deal with Pfizer; shares rise 19.7% - TradingView — Track All Markets
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46% - 富途资讯
Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality - marketscreener.com
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
MRNA vs. NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing DealLearn Why - simplywall.st
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? - Stocktwits
Why Are Novavax (NVAX) Shares Soaring Today - The Globe and Mail
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely - StocksToTrade
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX) - MarketBeat
Novavax Strikes $500M Licensing Deal with Pfizer for Matrix-M Technology - timothysykes.com
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M (NASDAQ:NVAX) - Seeking Alpha
Pfizer and Novavax ink $530m vaccine delivery licensing deal - Pharmaceutical Technology
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million By Investing.com - Investing.com South Africa
Novavax inks license agreement with Pfizer - The Pharma Letter
Novavax signs licensing agreement with Pfizer for vaccine development - Reuters
Novavax (NASDAQ:NVAX) Stock Price Up 8%Still a Buy? - MarketBeat
Novavax Licenses Rights to Key Vaccine Component to Pfizer - The Wall Street Journal
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story - simplywall.st
Novavax’s Adjuvant Licensing Strategy Continues With Pfizer Pact - Citeline News & Insights
BTIG Reiterates Buy Rating for NVAX with $19 Price Target | NVAX Stock News - GuruFocus
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million - Investing.com Canada
Novavax Pops on Pfizer Licensing Deal - GuruFocus
Novavax's (NVAX) Buy Rating Reiterated at BTIG Research - MarketBeat
Novavax Stock Pops After Pfizer Licensing Agreement - Schaeffer's Investment Research
Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M - The Business Journals
Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant - marketscreener.com
Novavax, Inc. Enters into A License and Option Agreement with Pfizer Inc - marketscreener.com
Novavax (NVAX) Surges on Licensing Deal with Pfizer - GuruFocus
Novavax rises on licensing deal with Pfizer (NVAX:NASDAQ) - Seeking Alpha
Investor Outlook: Novavax, Inc. (NVAX) Shows Potential 59.66% Upside Despite Challenges - DirectorsTalk Interviews
Novavax Announces Entering into a License Agreement with Pfizer - PR Newswire
Novavax enters license agreement with Pfizer for vaccine development - marketscreener.com
Novavax Enters $30M Licensing Agreement with Pfizer for Matrix-M® - Intellectia AI
Novavax Signs License and Option Agreement With Pfizer - TradingView — Track All Markets
Novavax Enters $30M Licensing Agreement with Pfizer for Matrix-M Adjuvant - Intellectia AI
The Truth About Novavax Inc (NVAX): Comeback Season or Total Trap? - AD HOC NEWS
Aug Breakouts: Will Novavax Inc face regulatory challenges2025 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
Understanding the Setup: (NVAX) and Scalable Risk - Stock Traders Daily
Bank of America Securities Reaffirms Their Sell Rating on Novavax (NVAX) - The Globe and Mail
Novavax jumps as FDA clears COVID-19 vaccine - MSN
JPM26: Matrix-M Technology is central to Novavax’s strategy - Yahoo Finance
Novavax Shares Slide as Long-Term Analysis Flags High Risk - cedarkeybeacon.com
JP Morgan 2026: Novavax Shifting Towards Partnership-Driven Strategy - Pharmaceutical Executive
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novavax Inc Azioni (NVAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Draghia-Akli Ruxandra | Section 16 |
Nov 11 '25 |
Option Exercise |
0.00 |
14,257 |
0 |
14,257 |
| MCGLYNN MARGARET G | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,588 |
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
2.77%
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):